checkAd
    Startseite > Aktien > AB SCIENCE > Nachrichten
    AB SCIENCE Aktie
    1,9900
     
    EUR
    +0,30 %
    +0,0060 EUR
    Letzter Kurs 10.05.24 Tradegate
    1,9760
     
    EUR
    507 STK
    Geldkurs 10.05.24
    2,0050
     
    EUR
    499 STK
    Briefkurs 10.05.24
    ISIN: FR0010557264 · WKN: A1CXBG · SYM: A8D · Frankreich

    Neueste Nachrichten

    AB Science: A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient
    07.05.24 · globenewswire · AB SCIENCE
    AB Science: The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science
    02.05.24 · globenewswire · AB SCIENCE
    AB Science announces a slight delay in the publication of its 2023 annual financial report
    30.04.24 · globenewswire · AB SCIENCE
    AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
    03.04.24 · globenewswire · AB SCIENCE
    AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
    13.03.24 · globenewswire · AB SCIENCE
    AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development
    07.03.24 · globenewswire · AB SCIENCE
    AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company
    06.03.24 · globenewswire · AB SCIENCE
    AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
    01.03.24 · globenewswire · AB SCIENCE
    AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
    29.02.24 · globenewswire · AB SCIENCE
    AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS
    26.02.24 · globenewswire · AB SCIENCE
    AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
    26.01.24 · globenewswire · AB SCIENCE
    AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis
    15.01.24 · globenewswire · AB SCIENCE